Acurx Pharmaceuticals Analyst Ratings
Acurx Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2023 | 642.86% | HC Wainwright & Co. | → $13 | Reiterates | Buy → Buy |
| 08/15/2023 | 642.86% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 05/15/2023 | 700% | HC Wainwright & Co. | → $14 | Reiterates | Buy → Buy |
| 04/11/2023 | 700% | HC Wainwright & Co. | → $14 | Reiterates | → Buy |
| 03/17/2023 | 700% | HC Wainwright & Co. | → $14 | Reiterates | → Buy |
| 12/19/2022 | 700% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 10/20/2022 | 700% | Alliance Global Partners | → $14 | Initiates Coverage On | → Buy |
| 11/29/2021 | 585.71% | Maxim Group | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/13/2023 | 642.86% | HC Wainwright公司 | →$13 | 重申 | 購買→購買 |
| 2023年08月15日 | 642.86% | HC Wainwright公司 | $14→$13 | 維護 | 買 |
| 2023年05月15日 | 700% | HC Wainwright公司 | →$14 | 重申 | 購買→購買 |
| 04/11/2023 | 700% | HC Wainwright公司 | →$14 | 重申 | →購買 |
| 03/17/2023 | 700% | HC Wainwright公司 | →$14 | 重申 | →購買 |
| 2022年12月19日 | 700% | HC Wainwright公司 | →$14 | 開始承保 | →購買 |
| 10/20/2022 | 700% | 聯盟全球合作夥伴 | →$14 | 開始承保 | →購買 |
| 2021年11月29日 | 585.71% | Maxim集團 | →$12 | 開始承保 | →購買 |
What is the target price for Acurx Pharmaceuticals (ACXP)?
Acurx製藥公司(ACXP)的目標價是多少？
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on September 13, 2023. The analyst firm set a price target for $13.00 expecting ACXP to rise to within 12 months (a possible 642.86% upside). 7 analyst firms have reported ratings in the last year.
阿科克斯製藥公司(納斯達克代碼：ACXP)的最新目標價是由HC Wainwright&Co.於2023年9月13日報道的。這家分析公司將目標價定為13美元，預計ACXP將在12個月內上漲(可能上漲642.86%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Acurx Pharmaceuticals (ACXP)?
分析師對Acurx製藥公司(ACXP)的最新評級是多少？
The latest analyst rating for Acurx Pharmaceuticals (NASDAQ: ACXP) was provided by HC Wainwright & Co., and Acurx Pharmaceuticals reiterated their buy rating.
分析師對艾柯克製藥(納斯達克代碼：ACXP)的最新評級由HC Wainwright&Co.提供，艾柯克斯製藥重申其買入評級。
When is the next analyst rating going to be posted or updated for Acurx Pharmaceuticals (ACXP)?
Acurx PharmPharmticals(ACXP)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acurx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acurx Pharmaceuticals was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Acurx製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Acurx製藥的上一次評級是在2023年9月13日提交的，所以你應該預計下一次評級將在2024年9月13日左右的某個時候公佈。
Is the Analyst Rating Acurx Pharmaceuticals (ACXP) correct?
分析師對Acurx製藥公司(ACXP)的評級正確嗎？
While ratings are subjective and will change, the latest Acurx Pharmaceuticals (ACXP) rating was a reiterated with a price target of $0.00 to $13.00. The current price Acurx Pharmaceuticals (ACXP) is trading at is $1.75, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Acurx製藥(ACXP)評級被重申，目標價在0.00美元至13.00美元之間。Acurx PharmPharmticals(ACXP)目前的交易價格為1.75美元，在分析師的預測範圍內。